Drug Trial Radar · NCT05649761
A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
61
Planned (sponsor's estimate)
Start
May 29, 2019
Primary completion
Jul 10, 2020
Study completion Jan 23, 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection (a humanized anti-PD-1 monoclonal antibody)in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
QL1604 injectionDrug
Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
- maximum tolerated dose(MTD)Time frame: Up to 21 days after the first dose
- recommended phase II dose (RP2D)Time frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of The University of Chinese Academy of Sciences
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.